

# Jorge GÃ³mez-Miragaya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8043520/publications.pdf>

Version: 2024-02-01

6  
papers

205  
citations

1478505

6  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. <i>Oncogene</i> , 2019, 38, 7106-7112.	5.9	48
2	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019, 17, 2063-2076.	3.4	20
3	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1</i> -Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.9	17
4	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	4.8	62
5	Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1338208.	0.7	10
6	Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs. <i>PLoS ONE</i> , 2015, 10, e0131241.	2.5	48